glaucoma_net_ru
YouTube
camopht
www.worldglaucoma.org
Основные мероприятия ассоциации офтальмологов
medlab
bannerparasol
icglaucoma.org
Mobile
santen
ВК
appstore
varthamana2
icgs2018
nidek
Торика
Ассоциации
Beaver
Конгресс
профессор
facebook
Конгресс 2014
АйНьюс.РФ
eye5
Первая пятница декабря
Флаги
Шахматы
oftalmolog_club
askin_heid
конгресс 2018
Главная / Новости / A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
6 месяцев назад
13 февраля 2018

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty

Полный текст тут https://www.dovepress.com/articles.php?article_id=36765 

Mahmoud A Khaimi

Dean McGee Eye Institute, Oklahoma City, OK, USA

Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty.
Methods: This was a retrospective medical chart review conducted at a single US center. Data were collected on patients with glaucoma who underwent canaloplasty with or without cataract surgery, and were prescribed LE suspension 0.5% postoperatively. Outcomes evaluated included postsurgical inflammation (anterior chamber [AC] cells and flare), intraocular pressure (IOP), number of IOP-lowering medications, and postsurgical complications.
Results: Data were collected on 204 patients (262 eyes) with a mean (SD) age of 71.6 (11.3) years. The most frequent LE dosing regimens at day 1, week 1, and month 1 postsurgery were QID (92.3%; 241/261), TID (52.6%; 133/253), and QD (65.5%; 78/119), respectively. Inflammation (AC flare and cells), mostly mild, was noted in 33.2% (86/259) of eyes on postoperative day 1 and 8.6% (21/244) of eyes at month 1. Mean IOP and mean number of IOP-lowering medications were significantly reduced from baseline (P<0.001) at all time points postoperatively. Complete (no IOP-lowering medication) or qualified (use of ≤2 IOP-lowering medications) surgical success was achieved in 78.8% and 90.6% of eyes, respectively, at month 6 and 63.4% and 92.7% of eyes at month 36. The most frequently observed postoperative complication was hyphema in 48.7% (126/259) eyes at day 1, which decreased to 0.4% (1/244) of eyes by month 1. IOP ≥30 mmHg was noted in 13 (5.3%) eyes at postoperative week 1 and rarely thereafter, and no patient discontinued therapy because of an IOP increase.
Conclusion: These real-world data suggest that canaloplasty with or without cataract surgery managed postoperatively with LE suspension 0.5% is effective and safe in the glaucoma patient.

Голосование
Что "заставляет" Вас заниматься научными исследованиями?